Cytokinetics CYTK
Blum Robert (Director) plans to sell 52,500 CYTK shares, about $4.5M
- Form
- 144
- Filed
- Importance
- Routine
- Accession
- 0001950047-26-006752
- Approximate sale date: Jul 1, 2026
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
- Shares acquired by: Exercise of Stock Options; Restricted Stock Units
- 10b5-1 plan adopted: Dec 24, 2025
All of Blum Robert's insider filings, holdings and planned sales
Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):
- Sold 7,500 shares at $84.92 on Jul 1, 2026 · Form 4
- Sold 10 shares at $82.02 on Jul 13, 2026 · Form 4
- Sold 7,490 shares at $82.02 on Jul 13, 2026 · Form 4
- Sold 7,500 shares at $80.87 on Jul 27, 2026 · Form 4
- Sold 7,500 shares at $76.76 on Aug 10, 2026 · Form 4
- Sold 7,500 shares at $70.24 on Aug 31, 2026 · Form 4
- Sold 7,500 shares at $73.44 on Sep 14, 2026 · Form 4
- Sold 7,500 shares at $65.46 on Sep 28, 2026 · Form 4
Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- TG Therapeutics TGTX public float $2.5B, Jun 30, 2025
- Catalyst Pharmaceuticals CPRX public float $2.5B, Jun 30, 2025
- Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
- Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
- Carisma Therapeutics CARM
